Veterans’ Affairs (Extending Medication Chart Prescribing to Hospitals and Other Measures) Instrument 2015

The instrument organises the Scheme’s prescription, supply, claims and records architecture around several core concepts. Each is functionally described in the text and creates explicit regulatory mechanics.

• Prescription types and formality. Two discrete prescription categories are controlled: prescriptions other than medication-chart prescriptions (s 11A) and medication‑chart prescriptions (s 11B). For non‑chart prescriptions the Act prescribes duplicate paper or computer/compliant electronic forms with precise inscriptions and a signature requirement (s 11A(1)(a)(i)-(ii), (b)). For medication charts, a "medication chart" is explicitly a chart form approved by the Secretary and used for both prescribing and recording administration in residential care or hospitals (s 11B(6)-(7)). The scheme treats a completed medication-chart section as a prescription (s 11B(2)).

• Secretary approvals and delegated forms. The Secretary under the National Health Act has approval power over electronic/computer prescription forms and the form of medication charts (s 11A(1)(a)(ii)(E), 11A(iia)(B), 11A(iii), 11B(7)). The instrument relies on delegated administrative approvals rather than legislating detailed electronic-format rules in the text itself.

• Supply-authorised entities. Supply on the basis of medication‑chart prescriptions is limited: in residential care only a Community Pharmacist may supply (16AA(1)(a)); in hospitals either a Community Pharmacist or the Approved Hospital Authority may supply (16AA(1)(b)). This distinction separates supply rights by setting and supplier type.

• Chart validity and supply timing. Medication charts have defined periods of validity: a three-calendar-month period for residential care charts measured from the first prescription (16AA(3)), and a hospital-chart period ending on a date specified on the chart chosen from statutory options (s 11B(3)(f), 16AA(3A)). Community Pharmacists must ensure supply occurs during the period of validity and no later than any stop date (16AA(2)(b)(i)-(ii)).

• Quantity and repeat logic. The instrument sets rules for repeating supplies under a single medication‑chart prescription. A pharmacist may supply more than once beyond a maximum quantity only where the prescription indicates ongoing authorisation for the chart period or where a stop date and dose/frequency mean multiple supplies of the maximum are required before the stop date is reached (16AA(4)-(5)). Where neither of these apply, the pharmacist may supply only what is needed to give effect to the prescription up to the maximum quantity (16AA(5)). The instrument expressly links maximum quantities to provisions in the National Health Act, the PBS Schedule and the RPBS Schedule (16AA(4) note).

• Information and claims pathway. Community Pharmacists must collect patient concession/entitlement status and associated numbers at supply for both continued dispensing and medication-chart supplies (16AB(1)-(2)). That information must be included in the claim to the Commonwealth via the Claims Transmission System, as defined in the National Health Act (16AB(3)). Payment is conditional on compliance with the Scheme plus submission of a completed supply-certification form under the claims rules (s 25(1)(a)-(b) and notes following s 24).

• Record-keeping regimes. The instrument updates the record-retention matrix: section 45 establishes two‑year retention for supply documents except for dangerous drugs, continued dispensing and medication-chart supplies (s 45(1)). Sections 45A and 45B create specific two‑year retention obligations for continued-dispensing supportive documents (45A(1)(a)-(b)) and medication charts or copies annotated by the supplying Community Pharmacist (45B(1)).

• Software-default restriction. Both the non-chart and medication-chart prescription provisions prohibit use of computer programs that operate or may operate to default the prescription to indicate that only the specified brand is to be supplied for the purpose of subsection 103(2A) of the National Health Act (s 11A(3); s 11B(3)(e)). This is a technical constraint on prescribing/IT behaviour.

• Incorporation-by-reference and definitions. The instrument updates the incorporation‑by‑reference date for Scheme documents to 1 April 2015 (Schedule 1) and lists the RPBS Explanatory Notes and the PBS/Pharmaceutical Benefits Scheme in List A (Schedule 1). Schedule 2 revises and adds definitions such as “approved hospital”, “claims rules”, “electronic prescription”, “MPBS prescriber” and replaces occurrences of “RPBS prescriber” with “MPBS prescriber”.

Together, these concepts change the operational steps for prescribers, Community Pharmacists and hospital authorities around how prescriptions are written, how supplies are authorised and documented, how claims are validated and how records are retained. Decision nodes are delegated to the Secretary (approvals), the claims rules (claim format and supporting forms), and the Claims Transmission System (claim transmission and inclusion of concession numbers) as defined under the National Health Act.

The instrument allocates obligations, decisions and rights among the following principal actors.

• RPBS / MPBS prescribers. The text requires prescribers to prepare prescriptions in specified formats, provide specific fields and inscriptions, sign and date prescriptions and, for certain prescribers, record approval numbers (see s 11A(1)(a)-(f); s 11A(1)(e) requires Authorised Midwives and Authorised Nurse Practitioners to state their approval number under regulation 8A of the National Health Act 1953). For medication-chart prescribing, prescribers must complete chart sections with required particulars and ensure the chart contains required patient and institutional information (s 11B(3)(a)-(b), (c)). The instrument also prohibits prescribers using computer programs that default to brand-only settings (s 11A(3), 11B(3)(e)).

• Community Pharmacists. The instrument places multiple obligations on Community Pharmacists: supply limitations by setting (16AA(1)); a sighting requirement for charts or copies to confirm compliance with chart completion rules (16AA(2)(a)); annotation duties when supplying (16AA(2)(c): pharmacist’s name and approval number, supply ID, supply date); collection and submission of concession and entitlement data at time of supply (16AB(2)-(3)); and document retention responsibilities (s 45, 45A, 45B). The Community Pharmacist may be the only authorised supplier in certain settings (16AA(1)(a)).

• Approved Hospital Authorities. In approved hospitals an Approved Hospital Authority may supply on the basis of a medication chart (16AA(1)(b)). The form and content of hospital medication charts are approved by the Secretary (11B(7)), and charts used for hospital patients must specify an end-of-validity date chosen from statutory options (11B(3)(f)). Approved Hospital Authorities therefore acquire supply and record-keeping responsibilities under the hospital pathway.

• Patients (including concessional and dependants). The instrument requires collection at supply of whether the patient is a concessional beneficiary or dependant and of any concession or entitlement card numbers (16AB(2)). Patients therefore face new or reinforced documentation checks at the point of supply that are fed into claims.

• IT and form manufacturers / software vendors. The Secretary’s approval role for computer-generated prescriptions and electronic prescription forms (11A(1)(a)(ii)(E); 11A(iia)(B); 11A(iii)) turns vendors’ product acceptance into a compliance gate. Software must not operate or may operate to default to “brand only” settings (11A(3), 11B(3)(e)), meaning vendors must design user interfaces and default logic to avoid that prohibited behaviour.

• Medicare/Claims administrators and the Secretary. The instrument relies on the Claims Transmission System (as defined in subsection 99AAA(1) of the National Health Act 1953) for inclusion of entitlement information (16AB(3)) and on claims rules for the supply certification form (note after s 24 and s 25(1)(b)). The Secretary has approval functions for forms and medication-chart forms (11A(1)(a)(ii)(E), 11A(iia), 11A(iii), 11B(7)). These administrative entities therefore hold ex ante gatekeeper roles for electronic formats and ex post payment/claim validation.

• The Commonwealth / payor. Payment is conditioned on compliance with the Scheme and on submission of supply certification forms per s 25(1)(a)-(b). The Commonwealth (implicitly through Medicare/claims administrators) therefore decides payment in relation to the applicant’s compliance.

• State/Territory regulators for “dangerous drugs”. Section 45(3) defines “dangerous drug” by reference to state/territory law that may require special possession/cancellation/delivery of prescriptions; thus state/territory obligations intersect with the Scheme’s record-keeping obligations in respect of certain drugs.

Concentrations and distributions of impact:

• Concentrated administrative actions fall on Community Pharmacists (annotations, claims data, record retention) and prescribers (document completion and form compliance). Hospital authorities acquire organisational responsibilities where hospital medication charts are used.

• Diffuse effects fall on patients through documentation checks that feed into claims. The Commonwealth’s conditionality on payments centralises enforcement via claim acceptance/rejection and by the Secretary’s approvals for electronic tools and chart forms.

Decision-making and cost-bearing are therefore distributed: prescribers and pharmacists bear compliance costs and operational steps, the Secretary and claims administrators decide approval and claims admissibility, and the Commonwealth ultimately pays or withholds payments based on compliance and claim completeness (s 25(1)(a)-(b); 16AB(3)).

This instrument creates prescriptive duties for prescribers and pharmacists, and rights to supply and claim that are conditional on compliance.

Prescribers’ duties

• Form and content obligations for non‑chart prescriptions: prescribers must prepare prescriptions in duplicate on specified forms (approx. 18 cm x 12 cm), include the prescriber’s name and address and, unless s 11A(4) applies, the letters “RPBS” (or “DVA”), mark originals and duplicates with “pharmacist/patient copy” and “Medicare Australia/DVA copy” respectively, sign the prescription, state prior approval for authority prescriptions where applicable, date the prescription, record patient name and address, identify the pharmaceutical benefit, state quantity and repeats and, where not a ready‑prepared pharmaceutical benefit, indicate administration method (s 11A(1)(a)(i)-(iia), (b)-(i)).

• Medication-chart completion duties: where the patient is in residential care or an approved hospital, the prescriber completes a chart section with particulars sufficient to identify the pharmaceutical benefit, date, dose/frequency/route, the letters “RPBS” or “DVA”, and other chart content such as prescriber full name/address/PBS prescriber number, patient name and Medicare number, entitlement card numbers, residential care service ID or hospital patient’s address, and signs both the section and the chart cover page (except for electronic prescriptions) (s 11B(1)-(3)(a)-(c)).

• Authority prescription content: for authority prescriptions a prescriber must indicate prior approval where obtained (s 11A(1)(c)) and include authority numbers or streamlined authority codes where medication-chart authority prescriptions are written (11B(4)(a)-(b)).

• Avoiding duplicate same‑day prescriptions: a prescriber must not write a prescription that provides for supply of the same or equivalent pharmaceutical benefit to the same person if the prescriber has already written another such prescription for that person on the same day (s 11A(2)(a)). Prescriptions must not be for more than one person (s 11A(2)(b)).

Pharmacists’ duties and rights

• Sight and verify medication charts or acceptable copies before supply (16AA(2)(a)(i)-(ii)).

• Ensure supply date falls within chart validity and not past any stop date (16AA(2)(b)).

• Annotate the chart or copy at supply with the Community Pharmacist’s name and approval number under Regulation 8A (if any), an identification number for the supply and the date of supply (16AA(2)(c)).

• Observe constraints on multiple supplies and maximum quantities in accordance with the chart and PBS/National Health Act rules (16AA(4)-(6)).

• Collect concession/entitlement status and card/entitlement numbers at time of supply for continued dispensing and medication-chart supplies and include that information in claims via the Claims Transmission System (16AB(2)-(3)).

• Keep specified documents for at least two years depending on supply type: general prescription‑based supplies (s 45(1)-(2)), continued dispensing records (45A(1)), and medication charts or copies annotated by the supplying pharmacist (45B(1)).

Administrative duties and rights

• Secretary approvals and rule-making roles: the Secretary approves electronic/computer forms and medication-chart forms (s 11A(1)(a)(ii)(E), 11A(iia), 11A(iii), 11B(7)). Claims rules made under the National Health Act determine the content and format of claims and the supply certification form referenced in s 25(1)(b) and notes following s 24.

• Claims-processing and payment discretion: payment of a claim is conditional on compliance with the Scheme and submission of a completed supply certification form per s 25(1)(a)-(b). The procedure for electronic claims is set out in the claims rules (notes after s 24).

Rights

• Supply rights for Community Pharmacists and Approved Hospital Authorities to supply on the basis of medication-chart prescriptions when the statutory and chart criteria are met (16AA(1)).

• Right to multiple supplies in limited circumstances where the prescription indicates ongoing authorisation or where a stop date/dose/frequency requires more than one supply of a maximum quantity before stop date (16AA(4)).

• Prescribers retain the right to prescribe but must comply with the prescribed writing requirements and Secretary approvals for certain electronic methods (11A and 11B).

The instrument links rights to payment: failure to comply with prescribed duties can affect payment, because claims require scheme compliance and submission of the supply certification form (s 25(1)(a)-(b)) and required fields must be included in the claims transmission (16AB(3)). Record-keeping duties enable retrospective verification of compliance, which feeds into payment decisions and administrative review.

The text does not create express criminal penalties or specific civil fines within the provided provisions. Enforcement mechanics are primarily administrative and financial, implemented through claim admissibility and conditional payment rules, Secretary approvals and record-keeping obligations.

Enforcement levers and mechanisms in the text

• Payment conditionality. Section 25 makes payment of a claim under the Scheme explicitly subject to compliance with the Scheme, especially section 24, and to submission of a completed supply certification form under the claims rules (s 25(1)(a)-(b)). This conditions Commonwealth payment on adherence to scheme rules. That is an administrative enforcement lever: failure to comply can lead to non-payment or claim rejection.

• Claims data requirements. Section 16AB(3) requires the supplier to include concession/entitlement information collected at the time of supply in the claim for payment via the Claims Transmission System. Non‑inclusion of these data fields could lead to claim refusal or later recovery actions as determined by the claims operations and rules under the National Health Act.

• Approval gatekeeping. The Secretary must approve in writing electronic prescription methods, forms and medication-chart forms under s 11A(1)(a)(ii)(E), 11A(iia)(B), 11A(iii) and s 11B(7). Administrative refusal, withdrawal or conditional approval of methods/forms constrains lawful use. Where prescribers or vendors use unapproved formats, claims may be refused for non-compliance.

• Record-keeping and auditability. Sections 45, 45A and 45B impose two‑year retention obligations for different classes of records. Those records enable retrospective audit and verification. While the text does not spell out auditing or recovery processes, retained records provide the factual basis for administrative review and claim recoupment under the broader National Health Act authorities and claims rules incorporated by reference.

• Cross-references to the National Health Act. The instrument repeatedly cross-references sections and mechanisms in the National Health Act 1953 (for example subsection 103(2A), 85A(2), 85B, 99AAA, and the claims rules under subsections 98AC(4) and 99AAA(8)). The National Health Act contains the statutory power base and enforcement machinery (not reproduced here), so enforcement actions are likely to be taken under those provisions where the Scheme identifies non-compliance or overpayment.

Absence of express new penalties in the text

• The instrument does not set out new criminal sanctions, civil pecuniary penalties, or explicit debarment mechanisms within the provided excerpt. Instead it links compliance to payment entitlement and administrative approvals, leaving sanction specifics to the claims rules and the National Health Act infrastructure. This means enforcement will primarily be through claim rejection, administrative recovery of payments, audits and Secretary-controlled approvals, as determined under the broader Acts and rules referenced.

Practical enforcement risk points

• Claims rejection or recovery for insufficient or missing claim data required under 16AB(2)-(3) and s 25.

• Disallowance of claims where prescriptions or medication-chart prescriptions fail to meet the writing requirements in s 11A or s 11B, including unsigned prescriptions, missing required fields, or use of unapproved electronic forms.

• Rejection of supply as unlawful where the supplier fails to have sighted the medication chart or copy as required by 16AA(2)(a), or fails to annotate the chart as required by 16AA(2)(c).

• Potential for administrative inquiry where the Secretary has not approved a computer/electronic form used by a prescriber (11A(1)(a)(ii)(E), 11A(iia)(B), 11A(iii)), and the claim is lodged.

Note on state/territory intersections

• For “dangerous drugs” as defined in s 45(3), state or territory laws may impose obligations about taking possession of and cancelling or delivering prescriptions to an authority. Those requirements interact with Scheme record-keeping and may produce additional compliance obligations separate from the federal claims apparatus. Failure to reconcile these overlapping requirements may produce administrative or regulatory friction.

In short, the instrument relies on administrative enforcement via payment conditioning, approval gates and record‑keeping rather than creating new standalone statutory offences in the text provided. Claims rules and the National Health Act framework supply the enforcement reach and penalties that can be applied where Scheme compliance is assessed and found wanting.

The instrument frequently cross-references and depends on provisions in the National Health Act 1953, the National Health (Pharmaceutical Benefits) Regulations 1960 and other statutes, creating dependencies and delegated rule-making points.

Primary legislative cross-references

• National Health Act 1953. The Secretary referred to throughout is “as defined in the National Health Act 1953” (see s 11A(1)(a)(ii)(E), 11A(iia), 11A(iii), 11B(7)). The instrument also cites and depends on multiple National Health Act provisions: the Claims Transmission System (subsection 99AAA(1)) is invoked in 16AB(3); maximum quantities are linked to paragraph 85A(2)(a), to the PBS Schedule and the RPBS Schedule in 16AA(4) note; subsection 103(2A) is invoked in the prohibition on default brand-only computer programs (11A(3), 11B(3)(e)); streamlined authority codes and authority approval number rules are referenced in 11B(4) (and the note on subsection 85B consequences). Claims rules are defined as rules made under subsections 98AC(4) and 99AAA(8) of the National Health Act (Schedule 2 definition). Section 24 notes the obligation to include a “supply certification form” and that for electronic claims the supply certification form is to be given electronically (claims rules). The instrument therefore presumes concurrent operation of the National Health Act and its delegated claims rules.

• National Health (Pharmaceutical Benefits) Regulations 1960. The instrument cross-references those Regulations multiple times, including in the prescription-form requirements (subparagraphs cited in the source e.g. subparagraph 19(1)(a)(ii), subregulation 19AA(7)), the definition of authority prescription and authority prescription forms, the regulation 8A approval number for midwives and nurse practitioners (11A(1)(e) referencing regulation 8A), and the repeat authorisation form referenced in Schedule 2. It aligns the Scheme’s medication-chart prescribing rules with the corresponding MCP rules in the Regulations (the note after s 16 explicitly states the intention to ensure MCP under the RPBS can only occur where it could occur under the National Health Regulations).

• Acts that define key terms. The instrument uses definitions and concepts from other Acts: “residential care service” is defined by the Aged Care Act 1997 (Schedule 2); “hospital treatment” is defined by s 121‑5 of the Private Health Insurance Act 2007 (Schedule 2); “Chief Executive Medicare” is defined by the Human Services (Medicare) Act 1973 (Schedule 2). These cross-references fold state or federal definitions into the Scheme’s obligations.

• State and Territory laws on “dangerous drugs”. Section 45(3) defines “dangerous drug” by reference to the law of the State or Territory in which the prescription is written, so the Scheme’s record-keeping obligations incorporate or at least respect local statutory custody/cancellation requirements for certain drugs.

Delegation and incorporation-by-reference

• Claims rules and the Secretary’s approvals create delegated instruments and administrative practice that will shape operational detail: the claims rules (defined per Schedule 2) prescribe the supply certification form, rules for electronic claims, and other claims architecture. The Secretary’s power to approve electronic forms and medication-chart forms delegates much of the technical specification and interoperability burden to administrative processes (11A(1)(a)(ii)(E); 11B(7)).

• Incorporation by reference. Schedule 1 is amended to incorporate documents as they exist on 1 April 2015, including the RPBS Explanatory Notes and the PBS/Pharmaceutical Benefits Scheme (Schedule 1). This imports interpretive materials and parts of the broader PBS text by reference, meaning Scheme interpretation may be shaped by those documents without changing primary legislation.

Potential interaction effects and implementation points

• Alignment required between the National Health Act’s claims/transmission architecture and the Scheme’s data requirements: s 16AB(3) requires that collected concession/entitlement data be included in claims via the Claims Transmission System (defined in subsection 99AAA(1) of the National Health Act). Claim-adjudication rules under the National Health Act will determine how missing or inconsistent data are handled.

• Electronic prescription approvals and software compliance have to heed both the Secretary’s approvals under the National Health Act and the ban on default brand-only indicators under s 11A(3) and s 11B(3)(e); vendors must reconcile the Scheme’s prohibition with any separate property or interface rules imposed by private vendors or other State/Territory systems.

• State/Territory dangerous‑drug rules may impose further custody/cancellation obligations on pharmacists that affect the Scheme’s document-retention rules in s 45. Pharmacists operating across jurisdictions must reconcile federal claims documentation and local statutory physical-prescription custody obligations.

• Authority prescriptions: the note at 11B(5) explicitly warns that absent required streamlined authority codes or approval numbers on authority prescriptions the special patient contribution in subsection 85B(4) of the National Health Act may not be payable by the Commonwealth, tying Scheme documentation to payment outcomes under National Health Act provisions.

In sum, the Scheme amendments are tightly integrated with delegated administrative instruments and other federal legislation. Implementation requires co-ordination between the Secretary’s approvals, the claims-rule architecture under the National Health Act, the PBS schedules incorporated by reference, hospital/residential-care forms, IT vendors and State/Territory dangerous‑drug custody laws.

The text shows a sequence of substitutions, omissions and insertions to existing Scheme provisions. The instrument itself is presented as a set of amendments (omissions and substitutions) rather than as a wholly new Act. The instrument records specific temporal anchors and prior trial activity. The concrete amendment actions and dates in the text include:

• Omission: Section 11C is explicitly omitted (6 Section 11C , "omit. omit."). The source indicates the deletion of that section without reproducing its prior content.

• Section 11A inserted or redrafted to set out detailed writing requirements for prescriptions other than medication-chart prescriptions (section headed 11A , Writing of prescriptions , prescriptions other than medication chart prescriptions). This provision establishes required form sizes, duplications, inscriptions, approvals and content requirements, plus same‑day and single‑person prohibitions (s 11A(1)-(3)).

• Section 11B is inserted and elaborated as the medication-chart prescription regime (the complete s 11B text specifying completion of chart sections, required fields, authority-prescription rules and medication‑chart approval), replacing prior headings (the original heading before s 11B is omitted , see item 4).

• Note to section 16 substituted. The note now states that medication-chart prescribing (MCP) was introduced in stages with trials in residential care and certain hospitals, and that the intention is to align MCP under RPBS with MCP under the National Health Regulations (item 7). This indicates a policy background and staged roll-out with a noted 1 April 2015 trial start at certain hospitals.

• Insertion of new section 16AA (Supply of pharmaceutical benefit on basis of medication chart prescription). This section duplicates or re-states supply rules: who may supply on the basis of a medication chart, pharmacist sighting and annotation duties, chart validity periods for residential care and hospital (16AA(3) and 16AA(3A)), and rules on maximum quantities and repeat supplies (16AA(4)-(6)). This was inserted after section 16.

• Insertion of 16AB (Information about status of person , continued dispensing and medication chart prescriptions) after s 16A (item 9). This new section sets out what concession and entitlement information suppliers must collect at supply and requires inclusion of that information in claims via the Claims Transmission System (16AB(1)-(3)).

• Omission of sections 24A and 24B (items 10 and 12), and replacement of section 25 with a revised claims and payment provision (item 13). The new s 25 conditions payment on compliance with section 24 and on submission of a completed supply certification form under the claims rules (25(1)(a)-(b)).

• Revisions to the calculation of pharmaceutical allowance components in section 37 (item 13A) include indexing arrangements and specific treatment for veterans, couples and war widows/widowers, with notes defining related terms. This substitution affects benefit valuation.

• Record-keeping sections revised: substitution and reintroduction of s 45 with clarified scope and lists of documents to retain (item 14), and insertion of s 45A (keeping documents,continued dispensing) and s 45B (keeping documents,medication chart prescriptions) with two‑year retention requirements.

• Schedule 1 (incorporated documents) updated: the reference date for the version of incorporated documents is changed to 1 April 2015 (item 15), and List A is updated to include RPBS Explanatory Notes and PBS/Pharmaceutical Benefits Scheme (item 16).

• Schedule 2 (Variations to the MRCA Pharmaceutical Benefits Scheme) performs extensive definitional edits: insertion and substitution of definitions, redefinition of “electronic prescription”, substitution of “MPBS prescriber” for “RPBS prescriber”, defining “claims rules”, and making the RPBS explanatory notes part of the incorporated documents. It also replaces references to “RPBS prescriber” with “MPBS prescriber” across the Scheme (item 17).

Temporal and staged introduction references

• The inserted note after section 16 records that MCP trials occurred first in certain residential care services and then that, on 1 April 2015, a trial of MCP at certain hospitals commenced. The note expressly states the intention that MCP under the RPBS be permitted only where it could occur under the National Health (Pharmaceutical Benefits) Regulations 1960. This places the amendment in a staged, trial-linked policy history.

• The incorporation-by-reference changes anchor interpretive and schedule documents to the versions “as they exist on 1 April 2015,” replacing previous anchors to 1 November 2013 in the omitted passages. This moves the Scheme’s baseline forward to the 2015 versions of guidance and schedule documents.

Net effect

• The amendment history in the text shows a move to formalise medication-chart prescribing and supply pathways, bring claims data requirements into alignment with Claims Transmission System processes, and create discrete record regimes for continuing-dispensing and chart-based supplies. It also centralises technical specification and claim formats into delegated approvals and claims rules, while updating incorporated interpretative materials to a 2015 baseline.

The excerpted instrument does not list or cite any judicial decisions, regulatory determinations or litigation history. No cases are named in the text provided. Accordingly, there is no direct litigation record included in the instrument itself to report.

Potential litigation and administrative dispute vectors suggested by the provisions

• Claims rejection or recoupment disputes. Because payment is conditioned on compliance with the Scheme and submission of a completed supply certification form (s 25(1)(a)-(b)), and because 16AB(3) requires specific claim data via the Claims Transmission System, suppliers whose claims are rejected or from whom payments are recovered could commence administrative review or judicial review actions seeking reversal, or disputes over whether claims rules were correctly applied. The instrument itself does not create litigation rules, but the claims conditionality is a likely source of disputes.

• Secretary approval decisions. The Secretary has approval power over electronic prescription methods and the form of medication charts (see s 11A(1)(a)(ii)(E), 11A(iia), 11A(iii), 11B(7)). Decisions to refuse approval, or to withdraw authorisation for particular electronic prescription processes or chart forms, could give rise to administrative law challenges for affected prescribers, software vendors or health services.

• Interpretation of “brand-only” default prohibition. The textual prohibition on computer programs that “operate, or may operate, to indicate on a prescription by default, for the purpose of subsection 103(2A) of the National Health Act 1953, that only the brand of Pharmaceutical benefit specified in the prescription is to be supplied” (s 11A(3); s 11B(3)(e)) could give rise to disputes about software behaviour, the threshold for “may operate”, and whether a particular vendor or prescriber’s workflow contravenes the prohibition. Disagreements about technical design and default settings could therefore be litigated or resolved in administrative forums.

• Cross-jurisdictional conflicts on “dangerous drugs”. Section 45(3) defines “dangerous drug” by reference to state or territory laws that may require pharmacists to take possession of, cancel or deliver prescriptions to a state authority. Conflicts between state custody requirements and federal claims/record-retention rules could produce compliance dilemmas and, potentially, legal disputes over which obligation prevails in particular circumstances.

• Authority prescription consequences. The instrument notes that if a streamlined authority code or an authority approval number must be written and is not, “the special patient contribution mentioned in subsection 85B(4) of the National Health Act 1953 may not be payable by the Commonwealth” (notes to 11B(4)/(5)). Disagreements about whether codes were required, whether the prescriber complied, and the financial consequences could lead to administrative appeals or litigation.

No reported cases in the instrument

• As the instrument does not record prior litigation or appellate decisions, practitioners must rely on the statutory text, the National Health Act and claims rules to anticipate dispute routes. The likely dispute locus is administrative review and merits/ judicial review challenges to claim denials, payment recoveries, or denial of approvals by the Secretary, rather than novel private-law causes of action created by the instrument itself.

Recommendation for practitioners facing disputes

• Preserve and compile the documentary trail required by the Scheme: signed prescriptions, annotated medication charts with pharmacist annotations (16AA(2)(c); 45B(1)), supply certification forms (s 25), and Claims Transmission System records (16AB(3)). Those documents are the statutory building blocks for defending claims rejections or payment recovery and will be essential in any administrative review or legal challenge grounded on the Scheme’s provisions.

In summary, the instrument contains no embedded litigation history; it creates administrative and financial dependencies that are plausible sources of dispute (claims, approvals, software-default interpretation, state/federal crossover), and disputes will primarily run through the administrative claims and review pathways referenced in the National Health Act and by the Secretary’s approvals.

The instrument contains a number of technical traps and potential unintended consequences that practitioners and administrators should recognise and plan for. These are concrete mechanics and interaction points drawn from the text.

1. Payment is conditional on a supply certification form, and electronic claims do not require the prescription to be provided with the claim. The text inserts notes to section 24 and a new s 25 which make payment contingent on compliance with section 24 and on submission of a completed supply certification form under the claims rules (note after s 24; s 25(1)(a)-(b)). Note (2) and (3) after s 24 clarify that for electronic claims the supply certification form is to be given electronically and that prescriptions need not be provided for electronic claims. Gotcha: a supplier may assume attaching the prescription to an electronic claim is necessary; the instrument says the supply certification form is required, not the prescription, and the claims rules will govern format. Failure to provide the supply certification form in the claims rules format risks claim rejection even where the prescription exists.

2. Secretary approvals necessary for electronic/computer forms and medication charts. Sections 11A(1)(a)(ii)(E), 11A(iia)(B), 11A(1)(a)(iii) and 11B(7) require Secretary approval for computer-generated prescription forms, electronic prescription forms and the form of medication charts. Gotcha: using an electronic prescription system that is not approved by the Secretary may render prescriptions non-compliant and jeopardise claims under s 25. Vendors and prescribers must confirm Secretary approvals before deployment.

3. The “brand-only default” prohibition on computer programs. Two provisions forbid using computer programs that “operate, or may operate, to indicate on a prescription by default … that only the brand … specified … is to be supplied” (11A(3); 11B(3)(e)). Gotcha: ambiguous product-design features that default to brand selection (for example, pre-selected brand names in search fields, or auto-population of brand-only checkboxes) may fall foul of this prohibition if they operate as default brand‑only indicators. Software vendors and pharmacists should audit UI defaults and workflow logic.

4. Same-day duplicate-prescription prohibition. Section 11A(2)(a) forbids a prescriber writing more than one prescription for the same person for the same or equivalent pharmaceutical benefit on the same day. Gotcha: in busy settings with transfers of care, prescribers may unintentionally produce duplicate prescriptions in different systems; identifying equivalent pharmaceutical benefits and recording cross-system coordination is necessary to avoid non-compliant duplicative entries.

5. Chart validity periods and hospital options. Medication charts for residential care end at the end of the third calendar month after the first prescription (16AA(3)), but hospital charts must specify an end date drawn from three options (1 month, 4 months, 12 months) as required by s 11B(3)(f) and 16AA(3A). Gotcha: for hospital charts the prescriber must pick and the chart must contain that specified end date; failing to select one of the permitted periods or to record the specified end date risks invalidating supplies taken after the unintended period.

6. Supply annotations required at time of supply. Section 16AA(2)(c) requires the Community Pharmacist to write their name and any approval number, an identification number for the supply and the date of supply on the medication chart or the copy. Gotcha: failing to perform these annotations will create non-compliant supplies and weak documentary support for claims, potentially leading to claim rejection or recovery.

7. Differing record-keeping rules depending on supply type. Section 45 excludes continued dispensing and medication-chart supplies from the general documents retention regime and instead establishes special regimes in 45A and 45B. Gotcha: pharmacies must maintain different archives and retrieval procedures depending on whether a supply was a continued-dispensing event, a medication-chart-supplied event, or an ordinary prescription supply. Process mapping and training will be required to avoid misfiling.

8. State/Territory “dangerous drug” custody requirements intersect federal retention rules. Section 45(3) makes the meaning of “dangerous drug” depend on state/territory law where the prescription is written. Gotcha: in some states pharmacists must physically surrender or cancel prescriptions; that duty may create friction with federal record-retention obligations and with providing copies to a claims auditor. Local legal advice will be necessary.

9. Authority prescriptions and streamlined authority codes. For authority prescriptions written in medication charts, 11B(4) requires either an authority prescription number or evidence of prior approval, or inclusion of one of the streamlined authority codes under subsection 85(7)(b), or those determined under 85A(2A). The note warns that omission of required codes or numbers can affect Commonwealth payment of special patient contributions under subsection 85B(4) of the National Health Act. Gotcha: failing to write required codes may reduce or eliminate Commonwealth payment components.

10. Incorporation by reference creates interpretive reliance. Schedule 1 changes the date of incorporated documents to 1 April 2015 and adds RPBS Explanatory Notes and the PBS to List A. Gotcha: practitioners must consult those specific versions of the documents; relying on earlier or later versions could produce inconsistent interpretation with the instrument’s operative references.

11. Terminology shift from RPBS prescriber to MPBS prescriber. Schedule 2 replaces “RPBS prescriber” with “MPBS prescriber” and defines that term to mean Approved Medical Practitioner, Authorised Midwife or Authorised Nurse Practitioner. Gotcha: administrative records, forms and IT systems that still use the older term may not map cleanly to the new definitions and could cause confusion during audits or claims processing.

12. Claims Transmission System dependency. 16AB(3) requires inclusion of concession/entitlement information in the claim using the Claims Transmission System defined in subsection 99AAA(1) of the National Health Act. Gotcha: claims stuck in legacy transmission formats or without correct field mapping risk rejection. Proper integration and testing with the Claims Transmission System are essential.

These “gotchas” are concrete implementation and compliance traps that follow directly from the instrument’s drafting. Each can produce claim rejection, payment reduction, or administrative challenge if not handled operationally.

This section sets out operational steps and checks for prescribers, Community Pharmacists, hospital authorities, IT vendors and claims administrators to meet the Scheme’s obligations as set out in the instrument.

Prescribers (non‑chart prescriptions)

• Use approved forms and formats. Prepare prescriptions in duplicate and use the approved paper size and inscriptions: approximately 18 cm by 12 cm, include prescriber name and address, letters “RPBS” or “DVA” (unless s 11A(4) applies), mark originals and duplicates as “pharmacist/patient copy” and “Medicare Australia/DVA copy” respectively (s 11A(1)(a)(i)-(ii)). For computer/computer-assisted prescriptions, ensure the program/form is approved in writing by the Secretary for the purpose (11A(1)(a)(ii)(E)).

• Avoid non‑approved electronic methods. Do not use electronic or other methods unless approved by the Secretary under s 11A(1)(a)(ii)(E), 11A(iia)(B) or 11A(1)(a)(iii). Confirm written approval exists and retain documentary evidence of that approval in case of audit.

• Complete mandatory fields. Sign after preparation (s 11A(1)(b)), include prior approval note for authority prescriptions (s 11A(1)(c)), date the prescription (s 11A(1)(d)), for Authorised Midwives/Authorised Nurse Practitioners include the approval number allocated under reg 8A (s 11A(1)(e)), provide patient name and address (s 11A(1)(f)), fully identify the pharmaceutical benefit (s 11A(1)(g)), specify quantity/units and number of repeats if to be repeated (s 11A(1)(h)), and indicate route/manner of administration where not a ready‑prepared benefit (s 11A(1)(i)).

• Avoid same-day duplications and multi‑patient prescriptions. Do not write more than one prescription for the same person for the same or equivalent pharmaceutical benefit on the same day (11A(2)(a)) and do not write prescriptions for more than one person (11A(2)(b)).

• Ensure authority prescriptions are correctly coded. Where prior approval is required, record “prior approval has been obtained” as relevant (s 11A(1)(c)). For medication-chart authority prescriptions, comply with 11B(4).

Medication-chart prescribers

• Use approved medication charts. Ensure the medication chart used is an approved form under s 11B(7). Complete the section of the chart in accordance with 11B(3) including particulars identifying the benefit, date, dose/frequency/route, the letters “RPBS” or “DVA”, prescriber full name/address/PBS prescriber number (if a PBS prescriber), patient details, facility ID or patient address according to setting, and sign as required (11B(3)(a)-(c)).

• Hospital chart validity selection. For hospital medication charts the prescriber must specify the chart’s period-of-validity end date and that date must be the last day of one of the options (1 month, 4 months or 12 months) starting on the day the first prescription is written (11B(3)(f)). Record that end date on the chart.

• Authority prescriptions in charts. For authority prescriptions, include the authority approval number or record prior approval/provide the streamlined authority code as appropriate (11B(4)(a)-(b)). Be aware of the note on consequences under subsection 85B(5) of the National Health Act for missing codes.

Community Pharmacists

• Verify charts and annotate. Before supplying on a medication‑chart prescription, sight the medication chart or an appropriate copy that shows compliance with 11B(3) and (4) (16AA(2)(a)(i)-(ii)). Annotate the chart or copy with the pharmacist’s name and any approval number under Reg 8A, a supply identification number and the date of supply (16AA(2)(c)). Retain a copy or the chart per 45B(1).

• Check validity periods and stop dates. Ensure the supply date is during the period of validity of the medication chart (residential: three-calendar-month rule 16AA(3); hospital: end date specified on chart 16AA(3A) referencing 11B(3)(f)) and no later than any stop date indicated in the prescription (16AA(2)(b)(i)-(ii)).

• Adhere to quantity and repeat rules. Only supply multiple times beyond the maximum where the prescription authorises ongoing supply for the chart validity period or where the stop date/dose/frequency necessitates more than one supply of a maximum quantity before the stop date (16AA(4)-(5)). Otherwise supply only the quantity needed to give effect to the prescription up to the maximum (16AA(5)).

• Collect concession and entitlement information at supply and include in claims. For both continued dispensing and medication-chart supplies, collect whether the patient is a concessional beneficiary or dependant, and respective card/entitlement numbers (16AB(2)(a)-(c)). Include those data in the claim for Commonwealth payment using the Claims Transmission System (16AB(3)). Ensure correct field mapping and transmissions to the Claims Transmission System as defined by subsection 99AAA(1) of the National Health Act.

• Preserve required records. Follow the three record regimes: general prescription-related documents retained for two years under s 45(1)-(2); continued dispensing supporting information retained two years under s 45A(1); medication charts or copies annotated by the pharmacist retained two years under s 45B(1).

IT vendors and software implementers

• Obtain Secretary approval where required. Seek written approval by the Secretary for any computer-generated or electronic prescription forms used for Scheme prescriptions (11A(1)(a)(ii)(E); 11A(iia)(B); 11A(1)(a)(iii); 11B(7)). Keep evidence of approvals.

• Avoid default brand-only logic. Ensure user interfaces and default logic do not “operate, or may operate” to indicate by default that only the brand specified is to be supplied for the purpose of subsection 103(2A) of the National Health Act (11A(3); 11B(3)(e)). Implement explicit user choices rather than brand-only defaults.

Claims administrators and Medicare

• Implement claims rules and supply-certification forms. Publish and enforce claims rules under subsections 98AC(4) and 99AAA(8) of the National Health Act that define the supply certification form and electronic submission formats. Ensure the Claims Transmission System accepts and validates concession/entitlement numbers collected under 16AB(2) and that the claim workflow checks for required supply-certification forms before payment is authorised (s 25(1)(a)-(b)).

• Leverage record-keeping on audit. When conducting claims audits or reconciliations, require the two-year retention documents set out in s 45, 45A and 45B as supporting evidence of compliance with prescription, supply and claims rules.

Hospitals and residential care services

• Ensure medication charts meet Secretary-approved form requirements and include the facility ID as required for residential care (11B(3)(b)(vii)) and full patient address if in hospital (11B(3)(b)(viii)). Implement internal processes that ensure prescribers select and record the chart end-of-validity date where applicable (11B(3)(f)).

• Establish coordination protocols between prescribers and Community Pharmacists to ensure medication charts are available (or compliant copies are produced) before supply, and that pharmacists can annotate the chart as required at the time of supply (16AA(2)(a), (c)).

Operational checklist

• Confirm Secretary approval for electronic prescription forms and medication-chart forms.

• Audit software for default brand-only logic and remediate interfaces.

• Train prescribers to include all mandatory fields specified in 11A and 11B and to avoid same-day duplicate prescriptions.

• Implement pharmacy workflow to sight charts/copies, annotate per 16AA(2)(c), collect concession/entitlement data (16AB(2)), transmit claims through the Claims Transmission System (16AB(3)) and attach/submit supply certification forms per claims rules.

• Maintain record-retention protocols: two years for the relevant documents depending on supply type (s 45, 45A, 45B).

• Integrate state/territory dangerous-drug custody obligations into pharmacy SOPs for handling physical prescriptions and scanned copies (45(3)).

• Keep documentary proof of approvals, authorisations and the supply-certification form for claims and audits.

These steps follow directly from the Scheme text and the incorporated references to the National Health Act and associated claims rules. Compliance requires administrative coordination between prescribers, Community Pharmacists, hospitals/residential-care services, IT vendors and claims administrators, and attention to the Secretary’s approval processes and the claims-rule formats referenced in the instrument.